Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on December 27, 2016, reporting an event that occurred on December 22, 2016. The filing addresses a significant regulatory and commercial development regarding the company's Argus II Retinal Prosthesis System.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a non-financial corporate event.
Material Changes
The primary material change is the announcement that the UK National Health System (NHS) will fund the Argus II "bionic eye" for a selective group of severely blind patients with Retinitis Pigmentosa (RP). This follows a positive recommendation from advisors to the UK Government's healthcare funding authority. Two implantation centers are being established: Manchester Royal Eye Hospital and London's Moorfields Eye Hospital.
Outlook, Risks, and Management Commentary
- Funding Mechanism: The treatment will be funded via the Commissioning through Evaluation (CtE) program, designed for treatments with significant promise while new clinical and patient data are collected.
- Precedent: The company notes that Argus II is already reimbursed under a similar "coverage with evidence development" program in France called "Forfait Innovation."
- Support Services: The hospitals and Second Sight will provide follow-up, rehabilitation, and support to patients receiving the implant.
- Risks/Contingencies: The filing does not explicitly list new risks, though the "evaluation" nature of the funding implies ongoing data collection requirements.
Investor Verification Checklist
- Verify the specific patient eligibility criteria for the NHS funding program.
- Confirm the timeline for the operational readiness of the Manchester and London implantation centers.
- Review the terms of the Commissioning through Evaluation (CtE) program to understand data collection obligations.
- Assess the potential revenue impact of UK reimbursement compared to existing markets like France.
- Confirm the company's name is Second Sight Medical Products, Inc., as the input metadata referenced Vivani Medical, Inc. incorrectly.